A new Crohn’s treatment that involves guselkumab showed outstandingly greater rates of endoscopic improvement, which are vital for reducing long-term complications.

Guselkumab, a medication with a mechanism of action that is new to inflammatory bowel disease (IBD) treatment, outperformed ...

University of Birmingham medical student Nikhil Mistry gained a prestigious top prize at the 2025 Dr Falk Pharma/Guts UK ...

A new study led by researchers at Mount Sinai Health System has identified distinct biological signatures in patients with ...

Intravenous induction followed by subcutaneous maintenance therapy with guselkumab is efficacious for adults with moderately ...

In this video, Joseph M. Runde, DO, attending physician in gastroenterology, hepatology and nutrition at Ann & Robert H. Lurie Children’s Hospital of Chicago and assistant professor of pediatrics at ...

In this video, Joseph M. Runde, DO, attending physician in gastroenterology, hepatology and nutrition at Ann & Robert H. Lurie Children’s Hospital of Chicago and assistant professor of pediatrics at ...

Here are four high-yield blue-chip pharmaceutical stocks positioned to outperform and offer huge total return potential.

A new discovery could change how type 1 diabetes is diagnosed and managed in individuals of African descent, researchers say.

The French biotech is developing a new drug approach in a disease market that’s projected to grow to $30 billion by 2030.

Changes in sleep metrics detected with wearable technology could serve as an inflammation marker and potentially predict IBD ...